Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD19/anti-CD3/anti-CD28 trispecific antibody CC312

A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) CD19, the T-cell surface antigen CD3, and the T-cell specific surface glycoprotein and co-stimulatory molecule CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/anti-CD3/anti-CD28 trispecific antibody CC312 targets and binds to CD3 and CD28 on T cells and CD19 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.
Synonym:anti-CD19/CD3/CD28 trispecific antibody CC312
CD19×CD3×CD28 trispecific antibody CC312
tri-specific T-cell engager CC312
TriTE CC312
Code name:CC 312
CC-312
CC312
Search NCI's Drug Dictionary